RSS
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
In August 2024, the American Journal of Psychiatry published a landmark update on PTSD by Arieh Shalev, MD, and colleagues at NYU — a comprehensive look at the diagnosis, neuroscience, and treatment of one of psychiatry’s most complex conditions. Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, and his co-host Kellie Newsome, PMHNP took a deep dive into that article in this five-part podcast series.
All five episodes are free to listen, with full transcripts available on each episode page. Follow Dr. Aiken and join the daily clinical conversation on social media:
All Episodes — PTSD 101
-
Episode 1 PTSD 101: Diagnosis
What is PTSD, and how is it diagnosed? An evidence-based overview grounded in the latest research.
-
Episode 2 PTSD 101: Causes
Why do some people develop PTSD after trauma and not others? What’s happening in the brain during PTSD.
-
Episode 3 PTSD 101: Therapy and Prevention
Which therapies work for PTSD, what happens in session, and how to help prevent PTSD when a patient calls you right after a trauma.
-
Episode 4 PTSD 101: Prazosin or SSRI?
Should you follow the FDA and prescribe SSRIs, or go off-label with the fabled prazosin? The evidence, weighed.
-
Episode 5 PTSD 101: Nine Off-Label Meds
A new medication is knocking on the door for FDA approval in PTSD — and it isn’t MDMA. Plus eight other off-label options, covered.
Enjoying these episodes? A 1-year CME subscription to The Carlat Psychiatry Podcast gives you access to quick 2–4 question post-tests after each episode, worth .25 CME credits each — adding up to around 13 CME credits per year, just for listening to a brief podcast each week.
More free series available. Catch up on The 10 Psychopharmacology Commandments, How to Start a Psych Medication, and Hidden Gems — all free in the podcast archive.
